Our Mission

To accelerate the cell-based bioeconomy by providing standardized stem cell product platforms that enable rapid clinical and commercial translation.

Why RoosterBio?

Leadership

Personally dedicated to customer success / Reimagining the future of stem cells
Responsible, respectful team, working and winning together

So Which Came First, The Rooster or the Egg?

A brief history with some personality

Company FAQs

Want to Join Our Team?

• Seeking An Exceptional Stem Cell Manufacturing Project Leader
• Seeking A Driven Sales Representative

Project Leader Sales Rep

Board of Directors

Rob Carlson, PhD
Rob is interested in the future role of biology as a human technology and is a founder of Biodesic, a consulting firm at the juncture of biology and other disciplines such as marketing, engineering, and investment. He is a serial entrepreneur and has worked to develop new biological technologies in both academic and commercial environments, focusing on molecular measurement and microfluidic systems. He has also developed and published a number of novel metrics for quantifying the impact and progress of biological technologies. Carlson is the author of the book Biology is Technology: The Promise, Peril, and New Business of Engineering Life, published in 2010 by Harvard University Press. Dr. Carlson earned a doctorate in Physics from Princeton University in 1997. Additional writing and blog can be found at www.synthesis.cc.

Becky Butler Cap, MBA
Becky Cap, a 20-year veteran of the life sciences industry, was named chief operating officer of San Antonio-based GenCure in February 2016.  GenCure, a subsidiary of BioBridge Global, is focused on providing and developing regenerative medicine and cellular therapy products.  GenCure’s mission is to realize the potential of donated human cells and tissue to save and enhance lives.

Cap, a native of Texas, earned a bachelor’s degree from Harvard University. She began her career at Dana-Farber Cancer Institute in Boston, where she gained clinical, laboratory and regulatory experience. 

While pursuing her MBA at Boston University’s Health Care Management Program, she moved to industry and began working for Eidetics, a consulting firm focused on informing biomedical product development, where her focus was largely on oncology product development.  She also has run her own consulting firm and worked with a number of local startups.

George W. Bickerstaff
George Bickerstaff joined the Board in July 2017. Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. He has served Novartis Pharma AG as its chief financial officer and held senior financial positions at IMS Health, Dun & Bradstreet and General Electric. He serves on numerous boards and is currently partner and managing director of M.M. Dillon & Co., an investment bank and financial advisory firm. He brings to the Board operational and international business experience that will be an asset to RoosterBio as we advance our products to commercialization and enter collaborative arrangements with other companies.

Margot Connor
Margot Connor of RoosterBio Inc. has over 25 years of diversified Life Science industry experience which includes executive level accountability for business operations, corporate development and M&A. Read full bio.

Jon A. Rowley, PhD (Chairman)
Founder and Chief Technical Officer of RoosterBio Inc., Dr. Jon A. Rowley, started RoosterBio in 2013 as part of his personal quest of having the biggest impact possible on the commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues, and tomorrow’s medical devices. Read full bio.


Advisors

R. Lee Buckler, BEd, LLB
Lee is the VP of Business and Corporate Development for RepliCel Life Sciences, Inc. Prior, he was the founder and managing director of Cell Therapy Group – a leading, boutique consultancy focused on the cell therapy and regenerative medicine industry. Since early 2000, Lee has been an executive in the cell therapy regenerative medicine industry. He has significant experience in both for-profit companies and non-profit organizations including Progenitor Cell Therapy, Malachite Management, Stem Cell Technologies, and the International Society for Cellular Therapy. https://replicel.com/about/executive-team/

Andras Forgacs, MBA
Andras is the co-founder of Modern Meadow as well as Organovo, which pioneered the use of 3D bio-printing to create human tissue for a range of medical applications. Prior to that, Andras was as Managing Director with Richmond Global, an international technology-focused venture fund, was a consultant in the New York office of McKinsey & Company focused on biopharma and private equity, and was a founding member of Citigroup’s corporate and investment banking e-commerce group. He is also co-founder and Chairman Emeritus of the international non-profit Resolution Project. http://modernmeadow.com/about-us/

Martin C. Peters, PhD
Martin C. Peters has over 12 years of professional experience developing and commercializing healthcare products from first-in-man through launch and life-cycle management. Martin is currently the Sr. Director of Program Leadership & Management at Biogen Idec and prior to this has served as Vice President of US Marketing for Novartis Vaccines, Sr. Director of Strategic Marketing for Aastrom Biosciences and as a Project Leader with the Boston Consulting Group. He holds a PhD from the University of Michigan where he was a Whitaker Foundation Fellow working on cell therapy for tissue engineering applications. He currently has six patents and over a dozen peer-reviewed articles covering cell therapy-related topics. LinkedIn Profile.

Prem Ramaswami, MBA
Prem has been a Product Manager at Google since 2006 and recently earned an MBA from the Harvard Business School, where he also served as a Teaching Fellow. At Google, Prem leads Google's health efforts in Google Search and Research. Prem has worked on projects such as Google Checkout, Google’s ecommerce shopping solution, and the Internet Bus Project aimed at increasing Internet penetration in India. Prem was also part of Google’s Network Infrastructure team as part of the Make the Web Faster Initiative launching Google Public DNS and started Google.org's Crisis Response Team. LinkedIn Profile.

Phil Vanek, PhD
Phil is General Manager of GE Healthcare’s Cell Bioprocessing business, a $6 billion strategy to revolutionize the world’s health by improving the quality, access and affordability of care. Phil joined GE from Lonza where he was Head of Innovation for Lonza’s Pharmaceutical division. Phil’s career has included a number of senior innovation, business and market development roles at Becton Dickinson, Invitrogen and Life Technologies, as well as two start-up biotechnology companies in the Washington, DC area. https://alliancerm.org/page/arm-secretary-phil-vanek

Makarand Jawadekar, PhD
A Pharmaceutical Research & Business executive, Pharmaceutical Sciences CMC area leader, expertise in Pharmaceutical Benchmarking, experience in Project &Portfolio Management, Novel Drug Delivery, and Controlled Drug Delivery, industry scientist, manager, and business strategist with over 31 years of experience. Continuous tenure at Pfizer Inc in diverse scientific, managerial, and business development positions. Dr. Jawadekar holds a PhD from the University of Minnesota in Pharmaceutics. LinkedIn Profile.

Aby Mathew, PhD

Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and is a co-developer of BioLife’s biopreservation media solutions. He holds a Ph.D. from Binghamton University and a B.S. from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife’s current commercial HypoThermosol® and CryoStor® product platforms and intellectual property foundation. Dr. Mathew was BioLife’s first Director of Manufacturing, established BioLife’s initial Quality system, and is currently BioLife’s Senior Vice President & Chief Technology Officer. Dr. Mathew is currently active in, or previously a member of, AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), the International Society for Cell Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology, International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of, the Board of Directors, and Advisory Panel, of the Parent’s Guide to Cord Blood Foundation, the Scientific Advisory Board of HemaCare Corporation, the founding Board of Directors of the Cord Blood Association, the NIST-AMTech National Cell Manufacturing Consortium, the California Institute for Regenerative Medicine (CIRM) Clinical Advisory Panel, and the Scientific Advisory Board of SAVSU Technologies. Dr. Mathew has obtained UCLA Corporate Governance Program Certification.

Investors

Please contact us for more information on investment opportunities.

Email Us